HomeInsightsStock Comparison

Suraksha Diagnostic Ltd vs Syngene International Ltd Stock Comparison

Suraksha Diagnostic Ltd vs Syngene International Ltd Stock Comparison

Last Updated on: Oct 25, 2026

Key Highlights

  • The Latest Trading Price of Suraksha Diagnostic Ltd is ₹ 298.9 as of 23 Oct 15:30 . The P/E Ratio of Suraksha Diagnostic Ltd changed from 42.2 on March 2025 to 36.9 on March 2026 . This represents a CAGR of -6.49% over 2 yearsThe P/E Ratio of Syngene International Ltd changed from 53.7 on March 2021 to 49.7 on March 2026 . This represents a CAGR of -1.28% over 6 years The Market Cap of Suraksha Diagnostic Ltd changed from ₹ 1342 crore on March 2025 to ₹ 1187 crore on March 2026 . This represents a CAGR of -5.95% over 2 yearsThe Market Cap of Syngene International Ltd changed from ₹ 21734 crore on March 2021 to ₹ 15724 crore on March 2026 . This represents a CAGR of -5.25% over 6 years The revenue of Suraksha Diagnostic Ltd for the Jun '26 is ₹ 88.73 crore as compare to the Mar '26 revenue of ₹ 82.2 crore. This represent the growth of 7.94% The revenue of Syngene International Ltd for the Jun '26 is ₹ 761.3 crore as compare to the Mar '26 revenue of ₹ 1058 crore. This represent the decline of -28.09% The ebitda of Suraksha Diagnostic Ltd for the Jun '26 is ₹ 31.53 crore as compare to the Mar '26 ebitda of ₹ 25.15 crore. This represent the growth of 25.37% The ebitda of Syngene International Ltd for the Jun '26 is ₹ 102.6 crore as compare to the Mar '26 ebitda of ₹ 319.6 crore. This represent the decline of -67.9% The net profit of Suraksha Diagnostic Ltd changed from ₹ 7.67 crore to ₹ 12.85 crore over 9 quarters. This represents a CAGR of 25.78% The net profit of Syngene International Ltd changed from ₹ 75.7 crore to ₹ -9 crore over 9 quarters. This represents a CAGR of NaN% The Dividend Payout of Suraksha Diagnostic Ltd changed from 0.76 % on March 2026 to 0.76 % on March 2026 . This represents a CAGR of 0.00% over 1 yearsThe Dividend Payout of Syngene International Ltd changed from 10.18 % on March 2022 to 16.52 % on March 2026 . This represents a CAGR of 10.17% over 5 years .

About Suraksha Diagnostic Ltd

  • Suraksha Diagnostic Limited was incorporated as Suraksha Diagnostic Private Limited' as a private limited company dated March 15, 2005, issued by the Deputy Registrar of Companies, West Bengal at Kolkata.
  • Subsequently, Company was converted into a public limited company and the name of Company was changed to Suraksha Diagnostic Limited', and a fresh certificate of incorporation dated July 16, 2024, was issued by the Registrar of Companies, Central Processing Centre. The Company is mainly engaged in running diagnostic centres for carrying out various pathological and radiological testing and medical consultation services in in East India.
  • In addition to integrated pathology and radiology testing services, it also offer omnichannel medical consultation services via online and offline modes to customers through 43 of its diagnostic centres which house 120 polyclinic chambers hosting 750+ doctors.

About Syngene International Ltd

  • Syngene International Limited is an integrated research, development and manufacturing services organization serving global pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemical sectors.
  • Headquartered in India, the operations are driven by its highly qualified teams comprising 5641 scientists and its state-of-the-art facilities, spread over 2.5 million sq. ft., across 3 locations in India: Bangalore, Hyderabad and Mangalore.
  • The Company operate into 4 business divisions comprising of Discovery Services, Development Services, Manufacturing Services and the Dedicated Centers. Syngene International Limited was incorporated at Bangalore in 1993.
  • The Company was promoted by Biocon and Kiran Mazumdar Shaw, a promoter of Biocon Limited.
  • The Company's health-related services extend across all major therapeutic areas and modalities.

FAQs for the comparison of Suraksha Diagnostic Ltd and Syngene International Ltd

Which company has a larger market capitalization, Suraksha Diagnostic Ltd or Syngene International Ltd?

Market cap of Suraksha Diagnostic Ltd is 1,556 Cr while Market cap of Syngene International Ltd is 14,810 Cr

What are the key factors driving the stock performance of Suraksha Diagnostic Ltd and Syngene International Ltd?

The stock performance of Suraksha Diagnostic Ltd and Syngene International Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Suraksha Diagnostic Ltd and Syngene International Ltd?

As of October 25, 2026, the Suraksha Diagnostic Ltd stock price is INR ₹298.9. On the other hand, Syngene International Ltd stock price is INR ₹366.9.

How do dividend payouts of Suraksha Diagnostic Ltd and Syngene International Ltd compare?

To compare the dividend payouts of Suraksha Diagnostic Ltd and Syngene International Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions